RI S2318 | 2020 | Regular Session
Status
Spectrum: Partisan Bill (Democrat 5-0)
Status: Introduced on February 5 2020 - 25% progression, died in committee
Action: 2020-03-05 - Committee recommended measure be held for further study
Pending: Senate Health and Human Services Committee
Text: Latest bill text (Introduced) [PDF]
Status: Introduced on February 5 2020 - 25% progression, died in committee
Action: 2020-03-05 - Committee recommended measure be held for further study
Pending: Senate Health and Human Services Committee
Text: Latest bill text (Introduced) [PDF]
Summary
Requires pharmaceutical drug manufacturers and pharmacy benefit managers to provide wholesale acquisition cost/drug prices/rebates/fees/drug sales information to DOH/Insurance Commissioner yearly.
Title
Drug Cost Transparency Act
Sponsors
| Sen. Dominick Ruggerio [D] | Sen. Maryellen Goodwin [D] | Sen. Michael McCaffrey [D] | Sen. Joshua Miller [D] |
| Sen. Cynthia Coyne [D] |
History
| Date | Chamber | Action |
|---|---|---|
| 2020-03-05 | Senate | Committee recommended measure be held for further study |
| 2020-02-28 | Senate | Scheduled for hearing and/or consideration (03/05/2020) |
| 2020-02-05 | Senate | Introduced, referred to Senate Health and Human Services |
Rhode Island State Sources
| Type | Source |
|---|---|
| Summary | https://status.rilegislature.gov/ |
| Text | https://webserver.rilegislature.gov/BillText20/SenateText20/S2318.pdf |
